Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | STK36 | Q9NRP7 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13951282 | 1.00 | MAPK14 (0.55) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 | |
| SCHEMBL4180204 | 0.89 | MAPK8 (0.59) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 | |
| SCHEMBL4186016 | 0.89 | MAPK14 (0.56) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 | |
| SCHEMBL4179286 | 0.88 | MAPK14 (0.44) | MAPK14MAPK8MAPK1 | |
| SCHEMBL4179363 | 0.85 | MAPK14 (0.49) | MAPK14MAPK8 | |
| SCHEMBL4180345 | 0.82 | MAPK14 (0.47) | MAPK14MAPK8 | |
| SCHEMBL4175970 | 0.79 | MEN1 (0.45) | MAPK1 | |
| SCHEMBL4175395 | 0.79 | USP2 (0.47) | MAPK14MAPK8MAPK1 | |
| SCHEMBL4181033 | 0.79 | MAPK14 (0.44) | MAPK14MAPK8MAPK1 | |
| SCHEMBL4178345 | 0.77 | MAPK14 (0.65) | MAPK14MAPK8RPS6KA4MAPK9RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | claimed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | MAPK14 1323/4885MAPK8 2442/4885RPS6KA4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.